



(12) Translation of
European patent specification

(11) NO/EP 3018211 B1

NORWAY

(19) NO
(51) Int Cl.
C12N 15/113 (2010.01)
A61K 31/7125 (2006.01)
C12N 15/11 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.11.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.07
(86)	European Application Nr.	15199455.5
(86)	European Filing Date	2011.08.31
(87)	The European Application's Publication Date	2016.05.11
(30)	Priority	2010.09.01, JP, 2010196032
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2612917, 2011.08.31
(73)	Proprietor	Nippon Shinyaku Co., Ltd., 14, Kisshoin Nishinosho Monguchicho, Minami-ku, Kyoto-shi,Kyoto 601-8550, Japan National Center of Neurology and Psychiatry, 1-1, Ogawa-Higashi-cho, 4-chome, Kodaira-shiTokyo 187-8551, Japan
(72)	Inventor	WATANABE, Naoki, Room 402, Ruvio II21-3 Sakura 1-chome, Tsukuba-shilbaraki 305-0003, Japan SATO, Youhei, Room 401, Ruvio II21-3 Sakura 1-chome, Tsukuba-shilbaraki 305- 0003, Japan TAKEDA, Shin'ichi, c/o National Center of Neurology and Psychiatry1-1 Ogawahigashicho 4-chome, Kodaira-shiTokyo 187-8551, Japan NAGATA, Tetsuya, c/o National Center of Neurology and Psychiatry1-1 Ogawahigashicho 4-chome, Kodaira-shiTokyo 187-8551, Japan
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	ANTISENSE NUCLEIC ACIDS
(56)	References Cited:	US-A1- 2010 168 212 WO-A1-2010/048586 POPPELWELL L J ET AL: "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials", NEUROMUSCULAR DISORDERS, PERGAMON PRESS, GB, vol. 20, no. 2, 1 February 2010 (2010-02-01), pages 102-110, XP026878306, ISSN: 0960-8966 [retrieved on 2010-01-15]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Antisenseoligomer som forårsaker hopping over det 53. eksonet i det humane dystrofingenet, bestående av en nukleotidsekvens komplementær til de 36. til 60. nukleotidene fra 5'-enden av det 53. eksonet i det humane dystrofingenet.
5
2. Antisenseoligomer ifølge krav 1, som er et oligonukleotid.
3. Antisenseoligomer ifølge krav 2, hvor sukkerdelen og/eller den fosfatbindende regionen til minst ett nukleotid som utgjør oligonukleotidet er modifisert.
10
4. Antisenseoligomer ifølge krav 3, hvor sukkerdelen av minst ett nukleotid som utgjør oligonukleotidet er en ribose hvor 2'-OH-gruppen er erstattet av en hvilken som helst valgt fra gruppen bestående av: OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br, og I, hvor R er en alkyl eller en aryl og R' er en alkyl.
15